Proactive Investors - Run By Investors For Investors

CelSci updates Phase 3 clinical trial of Advanced Head and Neck Cancer treatment

CEL-SCI Corporation (NYSE:CVM) CEO Geert Kersten sat down with Proactive Investors at the ThinkEquity Conference in New York. The Virginia-based biotech treats patients who are newly diagnosed with advanced primary squamous cell carcinoma of the head and neck with its drug Multikine before they receive surgery, radiation and/or chemotherapy.

 
View full CVM profile View Profile

CEL-SCI Corp. Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use